photo of Dr Rachel Conyers

Dr Rachel Conyers

Dr Rachel Conyers

Details

Role Team Leader / Clinical Research Fellow
Research area Stem Cell Medicine
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.

A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).

A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.

A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s...
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.

A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).

A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.

A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).

Top Publications

  • Singleton, AC, Redfern, J, Diaz, A, Koczwara, B, Nicholls, SJ, Negishi, K, La Gerche, A, Playford, D, Conyers, R, Cehic, DA, et al. Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia—An Australian Cardiovascular Alliance Perspective. Heart Lung and Circulation 2024
    view publication
  • Tripaydonis, A, Conyers, R. Adolescent survivor of childhood Acute Myeloid Leukaemia undertakes pregnancy with a severe anthracycline induced cardiomyopathy and risk taking behaviours. Case Reports in Internal Medicine 3(4) : 64 2024
    view publication
  • Wang, SS, Conyers, RK. Pediatric hypereosinophilia: FIP1L1-PDGFRA myeloproliferative disease in a 14-year-old male. Case Reports in Internal Medicine 3(2) : 2024
    view publication
  • Stern, K, Barak, S, Orme, L, Conyers, R, Seymour, J, Agresta, F. Reproductive concerns of children and adolescents with cancer: challenges and potential solutions. Clinical Oncology in Adolescents and Young Adults Volume 3: 63 -78 2024
    view publication
  • Schilstra, CE, McCleary, K, Fardell, JE, Donoghoe, MW, McCormack, E, Kotecha, RS, Lourenco, RDA, Ramachandran, S, Cockcroft, R, Conyers, R, et al. Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia. BMC Cancer 22(1) : 985 2024
    view publication

Page 1 of 14

Career information